HCP (NYSE:HCP) has been given a $32.00 price target by Morgan Stanley in a research report issued on Thursday. The brokerage currently has a “hold” rating on the real estate investment trust’s stock. Morgan Stanley’s price target would suggest a potential upside of 0.98% from the company’s current price.

Several other brokerages have also recently issued reports on HCP. Scotiabank initiated coverage on HCP in a research report on Monday, December 10th. They issued an “outperform” rating and a $32.00 price target on the stock. BMO Capital Markets restated a “buy” rating and issued a $33.00 price target on shares of HCP in a research report on Wednesday, February 13th. Robert W. Baird upgraded HCP from a “neutral” rating to an “outperform” rating in a research report on Monday, January 7th. TheStreet upgraded HCP from a “c” rating to a “b-” rating in a research report on Wednesday, February 13th. Finally, Zacks Investment Research upgraded HCP from a “sell” rating to a “hold” rating in a research report on Thursday, March 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $28.95.

HCP stock traded up $0.18 during trading on Thursday, hitting $31.69. The company had a trading volume of 4,180,484 shares, compared to its average volume of 3,255,182. The stock has a market capitalization of $15.05 billion, a PE ratio of 17.41, a price-to-earnings-growth ratio of 7.94 and a beta of 0.46. HCP has a 1-year low of $21.80 and a 1-year high of $32.23. The company has a quick ratio of 0.64, a current ratio of 0.64 and a debt-to-equity ratio of 0.85.

HCP (NYSE:HCP) last issued its quarterly earnings results on Wednesday, February 13th. The real estate investment trust reported $1.73 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $1.30. The firm had revenue of $441.92 million for the quarter, compared to analysts’ expectations of $445.81 million. HCP had a return on equity of 18.40% and a net margin of 57.41%. The firm’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.48 EPS. Analysts expect that HCP will post 1.74 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in HCP by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 75,247,949 shares of the real estate investment trust’s stock worth $1,980,527,000 after purchasing an additional 196,049 shares during the period. Vanguard Group Inc boosted its stake in shares of HCP by 0.3% during the 3rd quarter. Vanguard Group Inc now owns 75,247,949 shares of the real estate investment trust’s stock worth $1,980,527,000 after acquiring an additional 196,049 shares in the last quarter. BlackRock Inc. boosted its stake in shares of HCP by 4.1% during the 4th quarter. BlackRock Inc. now owns 46,146,172 shares of the real estate investment trust’s stock worth $1,288,861,000 after acquiring an additional 1,830,425 shares in the last quarter. Cohen & Steers Inc. boosted its stake in shares of HCP by 35.0% during the 4th quarter. Cohen & Steers Inc. now owns 22,898,362 shares of the real estate investment trust’s stock worth $639,551,000 after acquiring an additional 5,935,752 shares in the last quarter. Finally, Barrow Hanley Mewhinney & Strauss LLC boosted its stake in shares of HCP by 73.8% during the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 14,036,864 shares of the real estate investment trust’s stock worth $392,050,000 after acquiring an additional 5,960,734 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

HCP Company Profile

HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.

Featured Article: Understanding Compound Annual Growth Rate (CAGR)

Analyst Recommendations for HCP (NYSE:HCP)

Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.